


## Dacomitinib hydrate

<b>Cat. No.:</b>	HY-118263		
<b>CAS No.:</b>	1042385-75-0		
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>27</sub> ClFN <sub>5</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	488		
<b>Target:</b>	EGFR		
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 48.33 mg/mL (99.04 mM)

\* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.0492 mL	10.2459 mL	20.4918 mL
	5 mM	0.4098 mL	2.0492 mL	4.0984 mL
	10 mM	0.2049 mL	1.0246 mL	2.0492 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC)<sup>[1]</sup>.

### CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Cell Rep Med. 2023 Jan 10;100911.
- Mol Cancer Ther. 2018 Mar;17(3):603-613.
- Front Chem. 2020 Jul 28;8:596.
- Molecules. 2024 Jan 4, 29(1), 274.

---

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Lau SCM, et al. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. *Drugs*. 2019 Jun;79(8):823-831.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA